Last $4.20 USD
Change Today -0.07 / -1.64%
Volume 217.2K
MDGN On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

medgenics inc - unrestricted (MDGN) Snapshot

Open
$4.22
Previous Close
$4.27
Day High
$4.30
Day Low
$4.11
52 Week High
02/12/14 - $9.00
52 Week Low
11/25/14 - $4.10
Market Cap
100.9M
Average Volume 10 Days
151.1K
EPS TTM
--
Shares Outstanding
24.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDGENICS INC - UNRESTRICTED (MDGN)

Related News

No related news articles were found.

medgenics inc - unrestricted (MDGN) Related Businessweek News

No Related Businessweek News Found

medgenics inc - unrestricted (MDGN) Details

Medgenics, Inc., a medical technology and therapeutics company, is engaged in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops and commercializes Biopump platform technology that converts a piece of the patient’s own dermal skin tissue into a protein- and/or peptide-producing ‘Biopump’ to produce and deliver therapeutic proteins and/or peptides, and—when implanted under the patient’s skin—has the potential to deliver various months of protein/peptide therapy. Its product candidates include EPODURE Biopump, which is in Phase I/II clinical trials for the treatment of anemia in CKD and renal failure; and HEMODURE Biopump, which is under pre-clinical studies and produces Factor VIII for the treatment of patients with hemophilia. The company also develops INFRADURE Biopump that produces interferon-alpha for the treatment of patients with hepatitis C. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

36 Employees
Last Reported Date: 02/20/14
Founded in 2000

medgenics inc - unrestricted (MDGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $226.1K
Chief Financial Officer
Total Annual Compensation: $216.2K
Chief Scientific Officer
Total Annual Compensation: $193.9K
Compensation as of Fiscal Year 2013.

medgenics inc - unrestricted (MDGN) Key Developments

Medgenics Signs Research Collaboration with The Children's Hospital of Philadelphia

Medgenics has entered into a research collaboration with The Children's Hospital of Philadelphia. The partnership is aimed at paediatric rare and orphan genetic diseases and at accelerating the development of transformational new therapies for these underserved patients. The biobank at Children's Hospital of Philadelphia's Center for Applied Genomics has the larger biorepositories of paediatric genetic data in the world. Access to the genetic information in the CAG biobank is intended to enable researchers at both firms to work rapidly and efficiently to identify new rare and orphan disease targets and accelerate the development of novel therapies into clinical stage programs. Under the contract, Medgenics will pay USD 5 million to The Children's Hospital of Philadelphia and will also have a license to use the rare and orphan disease samples at the CAG biobank for the purpose of developing and commercialising therapeutic treatments and diagnostic targets for rare and orphan diseases.

Medgenics, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Medgenics, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating loss of $3,870,000 compared to $4,904,000 a year ago. Loss before taxes on income was $3,038,000 compared to $6,143,000 a year ago. Loss was $3,040,000 compared to $6,143,000 a year ago. Diluted loss per share was $0.21 compared to $0.33 a year ago. For the nine months, the company reported operating loss of $12,742,000 compared to $11,924,000 a year ago. Loss before taxes on income was $12,229,000 compared to $11,916,000 a year ago. Loss was $12,237,000 compared to $11,921,000 a year ago. Diluted loss per share was $0.68 compared to $0.68 a year ago.

Medgenics, Inc. to Present Initial Clinical Data from MDGN-201 Study at European Society of Gene and Cell Therapy Congress

Medgenics, Inc. announced that initial data from its ongoing Phase 1/2 clinical trial of MDGN-201, formerly known as EPODURE, will be presented at the 22nd Annual Congress of the European Society of Gene and Cell Therapy being held in The Hague, Netherlands from October 23, 2014 to October 26, 2014. The presentation entitled Prolonged Secretion of Physiological Levels of Autologous EPO by TARGT, will be presented by Dr. Garry Neil, Chief Scientific Officer. Dr. Neil will present data on the first three erythropoietin (EPO)-dependent patients from the ongoing clinical study of the TARGTsystem in dialysis patients with anemia due to end-stage renal disease or chronic kidney disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGN:US $4.20 USD -0.07

MDGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGN.
View Industry Companies
 

Industry Analysis

MDGN

Industry Average

Valuation MDGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDGENICS INC - UNRESTRICTED, please visit www.medgenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.